This site is now managed by the Commonwealth Department of Health and Aged Care.
Broad Health Condition Inflammatory and Immune System
Specific Health ConditionRheumatoid arthritis
Other muscular and skeletal disorders
Trial location outside Australia
Anticipated date of first participant enrolment1/01/2010
Patients with active rheumatoid arthritis in spite of disease modifying anti-rheumatic drugs (DMARD) treatment should after international guidelines be treated with biological medication. The patients are followed regularly by use of clinical and laboratory examination to assess the response to treatment. Ultrasonography has been shown to be a valid and reliable method for assessing the degree of inflammation (grey scale) and vascularization (power Doppler). The present study will explore ultrasonography as a method to differentiate between responders and non-responders early in the treatment period. In addition, the ultrasonographic findings will be compared to radiographic, laboratory and clinical responses to therapy.
Key inclusion criteria
Patients with rheumatoid arthritis Clinical indication for starting biological treatment
Minimum age18 Years
Maximum age85 Years
GenderBoth males and females
Key exclusion criteria
Not prosthesis in more than 5 of the joints examined by ultrasonography. Not enough knowledge of the Norwegian language to answer questionnaires.
Sponsor Primary Sponsor Type: Commercial sector/Industry
Primary Sponsor Name: Abbott Norge AS
Primary Sponsor Address: Martin Lingesv. 25, Box 1, N-1330 Fornebu
Primary Sponsor Country: Norway
Contact person for information and recruitmentHilde Berner Hammer
Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, 0319 Oslo
Email contact email@example.comNorway